)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Incannex Healthcare
Incannex Healthcare (IXHL) investor relations material
Incannex Healthcare Q1 2027 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 earnings summary12 Nov, 2026
Executive summary
IHL-42X advanced into patient dosing in the DREAMzz Phase 2 dose-optimization study in August 2026; completion is estimated for mid-2027.
PSX-001 development planning continues after positive Phase 2 PsiGAD1 results, FDA IND clearance for PsiGAD2, and MHRA scientific advice.
Financial highlights
No customer revenue in the quarter; material revenue is not expected until drug candidates receive approval.
Operating expenses were $3.436m vs. $6.794m YoY; operating loss was $3.436m vs. $6.794m.
Net loss improved to $1.938m from $6.407m; comprehensive loss was $1.548m vs. $6.184m.
Cash and cash equivalents were $68.267m at September 30, 2026, vs. $67.711m at June 30, 2026.
Operating cash flow was positive $521k vs. cash used of $9.163m YoY, reflecting working-capital movements and $3.4m of R&D tax receipts.
Outlook and guidance
Existing unrestricted cash is expected to fund planned operating expenses and capital expenditures for at least 12 months from the financial statement issuance date.
R&D expenses are expected to increase substantially as clinical and preclinical programs advance; future costs depend on trial scope, timing, enrollment and regulatory requirements.
DREAMzz dose-selection data are intended to inform the planned Phase 3 design; study completion is estimated for mid-2027.
Material revenue is not expected unless and until drug candidates are approved.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Incannex Healthcare
- Two director elections and auditor ratification headline the Dec. 17 virtual meeting.IXHL
Proxy filing - Two director elections and auditor ratification anchor the Dec. 17 virtual meeting.IXHLProxy filing
- Clinical investment grew; $14.55m cash was forecast to fund operations through Dec. 2024.IXHLQ2 2024
- Net loss improved to $19.3M, cash rose to $67.7M, and lead clinical programs advanced.IXHLQ4 2026
- Cash rose to $74.5M, net loss reached $16.8M, and $9.1M was spent on share repurchases.IXHLQ3 2026
- Late-stage oral therapies for OSA, GAD, and RA show strong efficacy and safety in Phase 2 trials.IXHLInvestor presentation
- Net loss reached $12.9M, cash rose to $68.9M, and 3.1M shares were repurchased.IXHLQ2 2026
- Annual meeting adjourned and rescheduled due to auditor proposal classification issue.IXHLProxy Filing
- Net loss widened to $5.4M as cash fell to $3.6M, with new financings offsetting going concern risks.IXHLQ1 2025
Next Incannex Healthcare earnings date
Q2 202712 Feb, 2027
Incannex Healthcare
Next Incannex Healthcare earnings date
Q2 202712 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Incannex Healthcare Inc. is a clinical-stage pharmaceutical company focused on developing medicinal cannabis and psychedelic pharmaceutical products. The company is engaged in the research, development, and commercialization of therapies aimed at addressing a range of medical conditions. These include obstructive sleep apnea (OSA), traumatic brain injury (TBI), lung inflammation, rheumatoid arthritis, inflammatory bowel disease, anxiety, addiction, and chronic pain. Incannex Healthcare's product portfolio consists of both cannabinoid-based formulations and novel psychedelic therapies, which are in various stages of clinical development. The company is headquartered in Sydney, Australia, and its shares are listed on the NASDAQ.